CNS Extracellular Vesicle Isolation Using Dual-Marker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating extracellular vesicles (EVs) from the central nervous system face challenges due to the use of single markers, which are not specific enough, and existing protocols exhibit variability, leading to difficulties in identifying and isolating EVs from complex samples like blood, where multiple cell types are represented.
Innovation Solution
A method involving a library of oligonucleotides and binding reagents that selectively bind to multiple surface markers such as GD1a, CD166, L1CAM, and others, allowing for the capture and isolation of CNS-derived EVs using a surface-based approach with anchoring and binding reagents, enabling the formation of complexes for specific EV isolation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single marker methods are used for EV isolation, then the process is simple, but the specificity and purity of isolated EVs is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the EV isolation process into multiple sequential steps: initial capture using one marker, release of non-specifically bound EVs, and secondary enrichment using a different marker. This multi-step segmented approach achieves high specificity (purifying EVs from complex samples like blood) while managing complexity through systematic breakdown of the isolation process into manageable stages.
Solution Approach 2:
The patent employs preliminary action by performing an initial capture step using one surface marker before the final isolation step. This preliminary capture allows for pre-enrichment of EVs, followed by release of non-specifically bound particles, and subsequent secondary enrichment with a different marker. This preliminary action ensures high specificity while maintaining a structured, multi-stage process.
2Reliability
If existing protocols are used for EV isolation, then the method is established, but variability and contamination remain high
Solution Approach 1:
The patent implements continuity of useful action through a continuous multi-step process where EVs are captured, released, and re-captured in sequence. This continuous action across multiple stages (initial capture → release → secondary enrichment) maintains reliability by consistently applying the same protocol steps, reducing variability while ensuring thorough purification of EVs from complex samples.
Solution Approach 2:
The patent applies feedback by using the results of the initial capture step to inform the secondary enrichment step. Non-specifically bound EVs are released and identified, providing feedback that guides the subsequent enrichment process with a different marker. This feedback mechanism ensures consistent, reliable isolation by adjusting each step based on previous results, reducing contamination while maintaining protocol standardization.
3Manufacturing precision
If multiple markers are used for EV isolation, then the purity of isolated EVs improves, but the complexity and time required increases
Solution Approach 1:
The patent uses preliminary action to perform initial capture with one marker before the final isolation step. This preliminary enrichment reduces the complexity of subsequent steps by pre-concentrating EVs, allowing the second marker to be applied more efficiently. This approach achieves high purity (isolating specific EV populations from blood) while managing time loss through optimized sequential processing.
Solution Approach 2:
The patent applies partial action by performing an initial capture step that enriches but does not fully purify EVs, followed by a secondary enrichment step that achieves the desired purity. This partial action in the first step, followed by targeted action in the second step, achieves high manufacturing precision (purity) while minimizing total time loss compared to attempting complete purification in a single step.
4Productivity
If single marker capture is used, then the process is fast, but the ability to isolate specific EV populations from complex samples is limited
Solution Approach 1:
The patent applies segmentation by dividing the isolation process into distinct stages: initial capture using one marker for high throughput, release of non-specifically bound EVs, and secondary enrichment using a different marker for high accuracy. This segmented approach maintains productivity by processing samples through standardized stages while achieving accurate identification of specific EV populations (e.g., platelet-derived EVs in blood) through the combined specificity of multiple markers.
Solution Approach 2:
The patent employs preliminary action by performing initial capture with one marker to rapidly enrich EVs from complex samples, maintaining high productivity. This preliminary step is followed by release and secondary enrichment with a different marker, which provides the accuracy needed for specific EV population identification. The preliminary action ensures throughput while the subsequent steps ensure precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a highly specific and efficient means to isolate CNS-derived EVs, reducing contamination and variability, and is scalable for high-throughput analysis, facilitating the understanding of EVs' role in neurodegenerative diseases and intercellular communication.
Implementation Method 1
selectively binding the EV of interest to: (i) a capture reagent releasably bound to the surface, wherein the surface further comprises an anchoring reagent; and (ii) a binding reagent
Data Source
AI summary
The invention relates to method and kits for highly specific isolation of surface marker displaying agents from the central nervous system by targeting at least two surface markers. The invention further relates to methods and kits for analyzing surface marker displaying agents and their contents.